Skip to main content
Signal8

Libtayo® (cemiplimab) Approved in the European Union (EU) for Extended Dosing and Faster Infusion Times Across Skin, Lung and Cervical Cancer Indications

$REGNPress releaseNov 17, 2026, 7:00 AM ETRead the release

The European Commission approved a flexible dosing schedule for Regeneron's PD-1 inhibitor Libtayo across all six EU-approved indications in skin, lung and cervical cancers. The approval adds a 700 mg every-six-week maintenance option after 12 weeks of 350 mg every three weeks, and allows infusion times to be cut from 30 minutes to 15 minutes after a well-tolerated first infusion. A U.S.

Key figures

Drug Name
Libtayo (cemiplimab)
Dosing regimen
700 mg every six weeks after initial 12 weeks of 350 mg every three weeks
Us sbla decision
March 2027
Eu indications covered
6
Infusion time reduction
30 minutes to 15-30 minutes after well-tolerated first infusion

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.